Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.

Investors interested in participating in the live call can dial:

  • 844-481-3008 – U.S.
  • 412-317-1892 – International

A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events

About Spectral AI 
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.

For Media and Investor Relations, please contact:

David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com

Staff

Recent Posts

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell…

32 minutes ago

ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI

BENGALURU, India, May 7, 2025 /PRNewswire/ -- European College of Sport and Exercise Physicians (ECOSEP) and…

3 hours ago

Grant Industries Selects Labbit LIMS to Drive Digital Transformation Across Its Regulated Labs

Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data…

3 hours ago

The Future of Ultrasound Reporting 

By Cecile Brosset, CEO of Sonio The landscape of ultrasound technology is rapidly evolving, driven…

20 hours ago

Beyond Medical Technologies Announces $2.5 Million Convertible Note Financing to Support Blockchain Attestation Platform

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

20 hours ago

Albert Einstein College of Medicine Launches Data Science Institute

Leveraging the Power of Data to Accelerate Scientific Discovery and Improve Health in the Bronx…

20 hours ago